Hims & Hers Health, Inc. Investors Urged to Lead Class Action Lawsuit After Significant Losses

Investor Alert: Sign Up Now for Hims & Hers Class Action

Hims & Hers Health, Inc., a notable player in telehealth, is currently at the center of a significant class action lawsuit due to allegations of deceptive practices that have led to considerable investor losses. The lawsuit targets the company's executives as well as the corporation itself for purported violations of the Securities Exchange Act of 1934. This alert serves to inform and urge affected investors to consider taking action before the approaching deadline.

Background on the Lawsuit

The root of the class action lawsuit stems from events that occurred during the 'Class Period,' which extends from April 29, 2025, to June 23, 2025. During this time, Hims & Hers publicly announced a collaboration with Novo Nordisk A/S, aiming to launch a new offering featuring Novo Nordisk's FDA-approved Wegovy®. This partnership initially raised optimism for investors, but it quickly turned into a focal point for legal scrutiny.

Allegations Against Hims & Hers

The complaints suggest that throughout the Class Period, Hims & Hers and its management communicated misleading information to investors and failed to disclose critical risks. Most notably, it is alleged that the company engaged in the deceptive promotion of counterfeit alternatives to Wegovy®, risking patient safety and violating the trust of their customer base. The fallout culminated on June 23, 2025, when Novo Nordisk publicly severed ties with Hims & Hers due to these malpractices. The announcement resulted in a staggering 34% drop in Hims & Hers' stock value, leading to significant losses for many investors.

Who Can Become a Lead Plaintiff?

According to the Private Securities Litigation Reform Act of 1995, any investors who purchased or acquired Hims & Hers securities during the Class Period have the opportunity to serve as lead plaintiffs in the lawsuit. The role of a lead plaintiff typically goes to someone who has experienced the most financial loss and can adequately represent the interests of all affected investors in the ongoing litigation. Importantly, anyone interested in serving as a lead plaintiff should act promptly, as the deadline for applications is set for August 25, 2025.

How to Take Action

Individuals who believe they qualify as lead plaintiffs are encouraged to reach out through Robbins Geller Rudman & Dowd LLP, the firm spearheading the case. Interested parties can fill out a contact form on their website to facilitate the process. Alternatively, they can make direct contact via phone or email with attorneys J.C. Sanchez or Jennifer N. Caringal for legal guidance. The law firm has indicated that it is prepared to navigate the complexities of securities litigation and ensure that all claims are thoroughly pursued.

About Robbins Geller Rudman & Dowd LLP

Robbins Geller is well-regarded as one of the leading law firms focused on protecting investors in securities fraud cases and handling shareholder litigation. With an established track record of success, having recovered over $2.5 billion for investors in 2024 alone, the firm possesses an impressive roster of attorneys skilled in navigating class action lawsuits. Their experience includes obtaining landmark settlements, including the most substantial recovery in history.

As the deadline approaches, affected investors of Hims & Hers Health, Inc. have a critical window to act. The pursuit of justice for financial losses not only supports individual investors but also reinforces accountability in corporate governance.

For more information on the class action or to learn how to participate, visit Robbins Geller's website.

Conclusion

Investors must stay vigilant during this turbulent period for Hims & Hers Health, Inc. The ongoing class action lawsuit represents a collective stand against corporate misconduct, and those who have suffered losses should not miss the opportunity to assert their rights.

For any further inquiries, reach out to Robbins Geller today to explore your options as part of this essential legal proceeding.